nodes	percent_of_prediction	percent_of_DWPC	metapath
Cinacalcet—CYP2D6—Fingolimod—multiple sclerosis	0.167	0.261	CbGbCtD
Cinacalcet—CYP3A4—Fingolimod—multiple sclerosis	0.106	0.166	CbGbCtD
Cinacalcet—CYP3A4—Methylprednisolone—multiple sclerosis	0.0685	0.107	CbGbCtD
Cinacalcet—CYP3A4—Triamcinolone—multiple sclerosis	0.0519	0.0811	CbGbCtD
Cinacalcet—CYP3A4—Mitoxantrone—multiple sclerosis	0.05	0.078	CbGbCtD
Cinacalcet—CYP3A4—Betamethasone—multiple sclerosis	0.0445	0.0695	CbGbCtD
Cinacalcet—CYP3A4—Prednisolone—multiple sclerosis	0.0439	0.0686	CbGbCtD
Cinacalcet—CYP3A4—Prednisone—multiple sclerosis	0.0415	0.0648	CbGbCtD
Cinacalcet—CYP2D6—Dexamethasone—multiple sclerosis	0.0407	0.0636	CbGbCtD
Cinacalcet—CYP3A4—Dexamethasone—multiple sclerosis	0.0259	0.0405	CbGbCtD
Cinacalcet—CASR—G alpha (i) signalling events—S1PR1—multiple sclerosis	0.00328	0.0333	CbGpPWpGaD
Cinacalcet—CASR—G alpha (q) signalling events—GPR65—multiple sclerosis	0.00317	0.0322	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—multiple sclerosis	0.00284	0.0288	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—RGS1—multiple sclerosis	0.00279	0.0283	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CXCL13—multiple sclerosis	0.00242	0.0245	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CCR1—multiple sclerosis	0.00242	0.0245	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—S1PR1—multiple sclerosis	0.00199	0.0202	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.0016	0.0163	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—GPR65—multiple sclerosis	0.0016	0.0162	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CCR2—multiple sclerosis	0.00156	0.0158	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—CXCL13—multiple sclerosis	0.00146	0.0149	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—CCR1—multiple sclerosis	0.00146	0.0149	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CNR1—multiple sclerosis	0.00144	0.0146	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.00129	0.0131	CbGpPWpGaD
Cinacalcet—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00125	0.0127	CbGpPWpGaD
Cinacalcet—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00125	0.0127	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—S1PR1—multiple sclerosis	0.00112	0.0114	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CCL5—multiple sclerosis	0.00111	0.0113	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—CCL3—multiple sclerosis	0.00104	0.0106	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—S1PR1—multiple sclerosis	0.00102	0.0103	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—PTGER4—multiple sclerosis	0.001	0.0102	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—CCR5—multiple sclerosis	0.001	0.0102	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—CXCR3—multiple sclerosis	0.00097	0.00984	CbGpPWpGaD
Cinacalcet—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000965	0.0098	CbGpPWpGaD
Cinacalcet—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000965	0.0098	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—RGS1—multiple sclerosis	0.000954	0.00969	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—CCR2—multiple sclerosis	0.000944	0.00958	CbGpPWpGaD
Cinacalcet—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000937	0.00951	CbGpPWpGaD
Cinacalcet—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000937	0.00951	CbGpPWpGaD
Cinacalcet—Body temperature increased—Cladribine—multiple sclerosis	0.000935	0.00358	CcSEcCtD
Cinacalcet—Abdominal pain—Cladribine—multiple sclerosis	0.000935	0.00358	CcSEcCtD
Cinacalcet—Skin disorder—Azathioprine—multiple sclerosis	0.000934	0.00358	CcSEcCtD
Cinacalcet—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000925	0.00939	CbGpPWpGaD
Cinacalcet—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000925	0.00939	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—GPR65—multiple sclerosis	0.000905	0.00918	CbGpPWpGaD
Cinacalcet—Hypotension—Azathioprine—multiple sclerosis	0.000899	0.00344	CcSEcCtD
Cinacalcet—Anaemia—Mitoxantrone—multiple sclerosis	0.000881	0.00337	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000876	0.00336	CcSEcCtD
Cinacalcet—Hypersensitivity—Cladribine—multiple sclerosis	0.000872	0.00334	CcSEcCtD
Cinacalcet—CASR—GPCR ligand binding—CNR1—multiple sclerosis	0.000871	0.00884	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—RGS1—multiple sclerosis	0.000867	0.0088	CbGpPWpGaD
Cinacalcet—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000854	0.00867	CbGpPWpGaD
Cinacalcet—Asthenia—Cladribine—multiple sclerosis	0.000849	0.00325	CcSEcCtD
Cinacalcet—Pruritus—Cladribine—multiple sclerosis	0.000837	0.0032	CcSEcCtD
Cinacalcet—Cough—Mitoxantrone—multiple sclerosis	0.000831	0.00318	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00083	0.00318	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—CCR1—multiple sclerosis	0.000827	0.0084	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000827	0.0084	CbGpPWpGaD
Cinacalcet—Convulsion—Mitoxantrone—multiple sclerosis	0.000825	0.00316	CcSEcCtD
Cinacalcet—Hypertension—Mitoxantrone—multiple sclerosis	0.000823	0.00315	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—GPR65—multiple sclerosis	0.000822	0.00834	CbGpPWpGaD
Cinacalcet—Arthralgia—Mitoxantrone—multiple sclerosis	0.000811	0.00311	CcSEcCtD
Cinacalcet—Chest pain—Mitoxantrone—multiple sclerosis	0.000811	0.00311	CcSEcCtD
Cinacalcet—Myalgia—Mitoxantrone—multiple sclerosis	0.000811	0.00311	CcSEcCtD
Cinacalcet—Diarrhoea—Cladribine—multiple sclerosis	0.000809	0.0031	CcSEcCtD
Cinacalcet—Arrhythmia—Prednisolone—multiple sclerosis	0.000802	0.00307	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—LINGO1—multiple sclerosis	0.000794	0.00806	CbGpPWpGaD
Cinacalcet—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000794	0.00806	CbGpPWpGaD
Cinacalcet—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000794	0.00806	CbGpPWpGaD
Cinacalcet—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000786	0.00301	CcSEcCtD
Cinacalcet—CASR—G alpha (i) signalling events—POMC—multiple sclerosis	0.000785	0.00797	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—CXCL10—multiple sclerosis	0.000784	0.00796	CbGpPWpGaD
Cinacalcet—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000783	0.00795	CbGpPWpGaD
Cinacalcet—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000783	0.00795	CbGpPWpGaD
Cinacalcet—Dizziness—Cladribine—multiple sclerosis	0.000782	0.003	CcSEcCtD
Cinacalcet—Infection—Mitoxantrone—multiple sclerosis	0.000772	0.00296	CcSEcCtD
Cinacalcet—Body temperature increased—Azathioprine—multiple sclerosis	0.00076	0.00291	CcSEcCtD
Cinacalcet—Abdominal pain—Azathioprine—multiple sclerosis	0.00076	0.00291	CcSEcCtD
Cinacalcet—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00076	0.00771	CbGpPWpGaD
Cinacalcet—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00076	0.00771	CbGpPWpGaD
Cinacalcet—Skin disorder—Mitoxantrone—multiple sclerosis	0.000755	0.00289	CcSEcCtD
Cinacalcet—Vomiting—Cladribine—multiple sclerosis	0.000752	0.00288	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CCR1—multiple sclerosis	0.000751	0.00763	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—CXCL13—multiple sclerosis	0.000751	0.00763	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000749	0.0076	CbGpPWpGaD
Cinacalcet—Rash—Cladribine—multiple sclerosis	0.000746	0.00286	CcSEcCtD
Cinacalcet—Dermatitis—Cladribine—multiple sclerosis	0.000745	0.00285	CcSEcCtD
Cinacalcet—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000744	0.00285	CcSEcCtD
Cinacalcet—Anorexia—Mitoxantrone—multiple sclerosis	0.000741	0.00284	CcSEcCtD
Cinacalcet—Headache—Cladribine—multiple sclerosis	0.000741	0.00284	CcSEcCtD
Cinacalcet—Arrhythmia—Triamcinolone—multiple sclerosis	0.000738	0.00282	CcSEcCtD
Cinacalcet—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000736	0.00282	CcSEcCtD
Cinacalcet—Hypotension—Mitoxantrone—multiple sclerosis	0.000727	0.00278	CcSEcCtD
Cinacalcet—Depression—Prednisone—multiple sclerosis	0.000725	0.00278	CcSEcCtD
Cinacalcet—Malnutrition—Methylprednisolone—multiple sclerosis	0.000717	0.00275	CcSEcCtD
Cinacalcet—Angioedema—Prednisolone—multiple sclerosis	0.000714	0.00273	CcSEcCtD
Cinacalcet—Hypersensitivity—Azathioprine—multiple sclerosis	0.000709	0.00271	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000708	0.00271	CcSEcCtD
Cinacalcet—Nausea—Cladribine—multiple sclerosis	0.000703	0.00269	CcSEcCtD
Cinacalcet—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000698	0.00267	CcSEcCtD
Cinacalcet—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000693	0.00265	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—TAGAP—multiple sclerosis	0.000689	0.00699	CbGpPWpGaD
Cinacalcet—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000684	0.00262	CcSEcCtD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000681	0.00691	CbGpPWpGaD
Cinacalcet—Convulsion—Prednisolone—multiple sclerosis	0.000677	0.00259	CcSEcCtD
Cinacalcet—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000676	0.00259	CcSEcCtD
Cinacalcet—CASR—GPCR ligand binding—CCL5—multiple sclerosis	0.000675	0.00685	CbGpPWpGaD
Cinacalcet—Hypertension—Prednisolone—multiple sclerosis	0.000675	0.00258	CcSEcCtD
Cinacalcet—Fatigue—Mitoxantrone—multiple sclerosis	0.00067	0.00257	CcSEcCtD
Cinacalcet—Arrhythmia—Dexamethasone—multiple sclerosis	0.000669	0.00256	CcSEcCtD
Cinacalcet—Arrhythmia—Betamethasone—multiple sclerosis	0.000669	0.00256	CcSEcCtD
Cinacalcet—Constipation—Mitoxantrone—multiple sclerosis	0.000665	0.00255	CcSEcCtD
Cinacalcet—Diarrhoea—Azathioprine—multiple sclerosis	0.000658	0.00252	CcSEcCtD
Cinacalcet—Angioedema—Triamcinolone—multiple sclerosis	0.000657	0.00252	CcSEcCtD
Cinacalcet—Angioedema—Methylprednisolone—multiple sclerosis	0.000655	0.00251	CcSEcCtD
Cinacalcet—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000644	0.00653	CbGpPWpGaD
Cinacalcet—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000644	0.00653	CbGpPWpGaD
Cinacalcet—Dizziness—Azathioprine—multiple sclerosis	0.000636	0.00244	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000636	0.00243	CcSEcCtD
Cinacalcet—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000633	0.00242	CcSEcCtD
Cinacalcet—Cough—Triamcinolone—multiple sclerosis	0.000627	0.0024	CcSEcCtD
Cinacalcet—Convulsion—Triamcinolone—multiple sclerosis	0.000623	0.00238	CcSEcCtD
Cinacalcet—Convulsion—Methylprednisolone—multiple sclerosis	0.000621	0.00238	CcSEcCtD
Cinacalcet—Hypertension—Triamcinolone—multiple sclerosis	0.000621	0.00238	CcSEcCtD
Cinacalcet—Hypertension—Methylprednisolone—multiple sclerosis	0.000619	0.00237	CcSEcCtD
Cinacalcet—Urticaria—Mitoxantrone—multiple sclerosis	0.000618	0.00237	CcSEcCtD
Cinacalcet—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000615	0.00235	CcSEcCtD
Cinacalcet—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000615	0.00235	CcSEcCtD
Cinacalcet—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000613	0.00622	CbGpPWpGaD
Cinacalcet—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000613	0.00622	CbGpPWpGaD
Cinacalcet—Myalgia—Triamcinolone—multiple sclerosis	0.000612	0.00234	CcSEcCtD
Cinacalcet—Vomiting—Azathioprine—multiple sclerosis	0.000612	0.00234	CcSEcCtD
Cinacalcet—Myalgia—Methylprednisolone—multiple sclerosis	0.000611	0.00234	CcSEcCtD
Cinacalcet—Arthralgia—Methylprednisolone—multiple sclerosis	0.000611	0.00234	CcSEcCtD
Cinacalcet—CASR—GPCR ligand binding—CCR5—multiple sclerosis	0.000608	0.00617	CbGpPWpGaD
Cinacalcet—Rash—Azathioprine—multiple sclerosis	0.000606	0.00232	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000606	0.00232	CcSEcCtD
Cinacalcet—Dermatitis—Azathioprine—multiple sclerosis	0.000606	0.00232	CcSEcCtD
Cinacalcet—Depression—Methotrexate—multiple sclerosis	0.000606	0.00232	CcSEcCtD
Cinacalcet—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000605	0.00614	CbGpPWpGaD
Cinacalcet—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000605	0.00614	CbGpPWpGaD
Cinacalcet—Headache—Azathioprine—multiple sclerosis	0.000603	0.00231	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—S1PR1—multiple sclerosis	0.000602	0.00611	CbGpPWpGaD
Cinacalcet—Angioedema—Betamethasone—multiple sclerosis	0.000596	0.00228	CcSEcCtD
Cinacalcet—Angioedema—Dexamethasone—multiple sclerosis	0.000596	0.00228	CcSEcCtD
Cinacalcet—Immune system disorder—Prednisone—multiple sclerosis	0.000589	0.00226	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—GPC5—multiple sclerosis	0.000586	0.00594	CbGpPWpGaD
Cinacalcet—Arrhythmia—Prednisone—multiple sclerosis	0.000583	0.00223	CcSEcCtD
Cinacalcet—Infection—Triamcinolone—multiple sclerosis	0.000583	0.00223	CcSEcCtD
Cinacalcet—Infection—Methylprednisolone—multiple sclerosis	0.000581	0.00223	CcSEcCtD
Cinacalcet—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000574	0.0022	CcSEcCtD
Cinacalcet—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000573	0.00219	CcSEcCtD
Cinacalcet—Paraesthesia—Prednisolone—multiple sclerosis	0.000573	0.00219	CcSEcCtD
Cinacalcet—Nausea—Azathioprine—multiple sclerosis	0.000571	0.00219	CcSEcCtD
Cinacalcet—Skin disorder—Methylprednisolone—multiple sclerosis	0.000569	0.00218	CcSEcCtD
Cinacalcet—Malnutrition—Prednisone—multiple sclerosis	0.000568	0.00218	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000568	0.00576	CbGpPWpGaD
Cinacalcet—Convulsion—Betamethasone—multiple sclerosis	0.000565	0.00216	CcSEcCtD
Cinacalcet—Convulsion—Dexamethasone—multiple sclerosis	0.000565	0.00216	CcSEcCtD
Cinacalcet—Hypertension—Betamethasone—multiple sclerosis	0.000563	0.00216	CcSEcCtD
Cinacalcet—Hypertension—Dexamethasone—multiple sclerosis	0.000563	0.00216	CcSEcCtD
Cinacalcet—Asthenia—Mitoxantrone—multiple sclerosis	0.000558	0.00214	CcSEcCtD
Cinacalcet—Myalgia—Betamethasone—multiple sclerosis	0.000555	0.00213	CcSEcCtD
Cinacalcet—Myalgia—Dexamethasone—multiple sclerosis	0.000555	0.00213	CcSEcCtD
Cinacalcet—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.00055	0.00558	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000548	0.00556	CbGpPWpGaD
Cinacalcet—Hypotension—Methylprednisolone—multiple sclerosis	0.000547	0.00209	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CCL3—multiple sclerosis	0.000535	0.00543	CbGpPWpGaD
Cinacalcet—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000534	0.00205	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000533	0.00204	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—CCR2—multiple sclerosis	0.000533	0.00541	CbGpPWpGaD
Cinacalcet—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000532	0.00204	CcSEcCtD
Cinacalcet—Infection—Dexamethasone—multiple sclerosis	0.000529	0.00203	CcSEcCtD
Cinacalcet—Infection—Betamethasone—multiple sclerosis	0.000529	0.00203	CcSEcCtD
Cinacalcet—Paraesthesia—Triamcinolone—multiple sclerosis	0.000527	0.00202	CcSEcCtD
Cinacalcet—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000526	0.00201	CcSEcCtD
Cinacalcet—Anaemia—Prednisone—multiple sclerosis	0.000525	0.00201	CcSEcCtD
Cinacalcet—Dyspnoea—Triamcinolone—multiple sclerosis	0.000523	0.002	CcSEcCtD
Cinacalcet—Nervous system disorder—Betamethasone—multiple sclerosis	0.000522	0.002	CcSEcCtD
Cinacalcet—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000522	0.002	CcSEcCtD
Cinacalcet—Angioedema—Prednisone—multiple sclerosis	0.000519	0.00199	CcSEcCtD
Cinacalcet—Dyspepsia—Triamcinolone—multiple sclerosis	0.000516	0.00198	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—PTGER4—multiple sclerosis	0.000515	0.00523	CbGpPWpGaD
Cinacalcet—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000515	0.00197	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—RGS1—multiple sclerosis	0.000512	0.0052	CbGpPWpGaD
Cinacalcet—Anorexia—Dexamethasone—multiple sclerosis	0.000507	0.00194	CcSEcCtD
Cinacalcet—Anorexia—Betamethasone—multiple sclerosis	0.000507	0.00194	CcSEcCtD
Cinacalcet—Urticaria—Prednisolone—multiple sclerosis	0.000507	0.00194	CcSEcCtD
Cinacalcet—Fatigue—Triamcinolone—multiple sclerosis	0.000506	0.00194	CcSEcCtD
Cinacalcet—Fatigue—Methylprednisolone—multiple sclerosis	0.000505	0.00193	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CXCR3—multiple sclerosis	0.000498	0.00505	CbGpPWpGaD
Cinacalcet—Hypotension—Dexamethasone—multiple sclerosis	0.000497	0.0019	CcSEcCtD
Cinacalcet—Hypotension—Betamethasone—multiple sclerosis	0.000497	0.0019	CcSEcCtD
Cinacalcet—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000497	0.00504	CbGpPWpGaD
Cinacalcet—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000497	0.00504	CbGpPWpGaD
Cinacalcet—Vomiting—Mitoxantrone—multiple sclerosis	0.000494	0.00189	CcSEcCtD
Cinacalcet—Immune system disorder—Methotrexate—multiple sclerosis	0.000493	0.00189	CcSEcCtD
Cinacalcet—Convulsion—Prednisone—multiple sclerosis	0.000492	0.00188	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—CNR1—multiple sclerosis	0.000492	0.00499	CbGpPWpGaD
Cinacalcet—Hypertension—Prednisone—multiple sclerosis	0.00049	0.00188	CcSEcCtD
Cinacalcet—Rash—Mitoxantrone—multiple sclerosis	0.00049	0.00188	CcSEcCtD
Cinacalcet—Dermatitis—Mitoxantrone—multiple sclerosis	0.00049	0.00188	CcSEcCtD
Cinacalcet—Headache—Mitoxantrone—multiple sclerosis	0.000487	0.00187	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—GPR65—multiple sclerosis	0.000485	0.00493	CbGpPWpGaD
Cinacalcet—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000485	0.00186	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000485	0.00186	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CCR2—multiple sclerosis	0.000484	0.00491	CbGpPWpGaD
Cinacalcet—Arthralgia—Prednisone—multiple sclerosis	0.000484	0.00185	CcSEcCtD
Cinacalcet—Myalgia—Prednisone—multiple sclerosis	0.000484	0.00185	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00048	0.00184	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000479	0.00183	CcSEcCtD
Cinacalcet—Paraesthesia—Betamethasone—multiple sclerosis	0.000478	0.00183	CcSEcCtD
Cinacalcet—Paraesthesia—Dexamethasone—multiple sclerosis	0.000478	0.00183	CcSEcCtD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000477	0.00484	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—POMC—multiple sclerosis	0.000475	0.00482	CbGpPWpGaD
Cinacalcet—Malnutrition—Methotrexate—multiple sclerosis	0.000475	0.00182	CcSEcCtD
Cinacalcet—Hypersensitivity—Prednisolone—multiple sclerosis	0.00047	0.0018	CcSEcCtD
Cinacalcet—Dyspepsia—Dexamethasone—multiple sclerosis	0.000469	0.00179	CcSEcCtD
Cinacalcet—Dyspepsia—Betamethasone—multiple sclerosis	0.000469	0.00179	CcSEcCtD
Cinacalcet—Urticaria—Triamcinolone—multiple sclerosis	0.000466	0.00178	CcSEcCtD
Cinacalcet—Urticaria—Methylprednisolone—multiple sclerosis	0.000465	0.00178	CcSEcCtD
Cinacalcet—CASR—GPCR ligand binding—CCL2—multiple sclerosis	0.000465	0.00472	CbGpPWpGaD
Cinacalcet—Body temperature increased—Triamcinolone—multiple sclerosis	0.000464	0.00178	CcSEcCtD
Cinacalcet—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000463	0.00177	CcSEcCtD
Cinacalcet—Decreased appetite—Betamethasone—multiple sclerosis	0.000463	0.00177	CcSEcCtD
Cinacalcet—Decreased appetite—Dexamethasone—multiple sclerosis	0.000463	0.00177	CcSEcCtD
Cinacalcet—Nausea—Mitoxantrone—multiple sclerosis	0.000462	0.00177	CcSEcCtD
Cinacalcet—Infection—Prednisone—multiple sclerosis	0.000461	0.00176	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00046	0.00176	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00046	0.00176	CcSEcCtD
Cinacalcet—Fatigue—Betamethasone—multiple sclerosis	0.000459	0.00176	CcSEcCtD
Cinacalcet—Fatigue—Dexamethasone—multiple sclerosis	0.000459	0.00176	CcSEcCtD
Cinacalcet—Nervous system disorder—Prednisone—multiple sclerosis	0.000455	0.00174	CcSEcCtD
Cinacalcet—Skin disorder—Prednisone—multiple sclerosis	0.00045	0.00172	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CNR1—multiple sclerosis	0.000447	0.00454	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CCR1—multiple sclerosis	0.000444	0.00451	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CXCL13—multiple sclerosis	0.000444	0.00451	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000443	0.0045	CbGpPWpGaD
Cinacalcet—Anorexia—Prednisone—multiple sclerosis	0.000442	0.00169	CcSEcCtD
Cinacalcet—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000439	0.00446	CbGpPWpGaD
Cinacalcet—Anaemia—Methotrexate—multiple sclerosis	0.000439	0.00168	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000435	0.00167	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000435	0.00167	CcSEcCtD
Cinacalcet—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000432	0.00166	CcSEcCtD
Cinacalcet—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000431	0.00165	CcSEcCtD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000427	0.00434	CbGpPWpGaD
Cinacalcet—Urticaria—Dexamethasone—multiple sclerosis	0.000423	0.00162	CcSEcCtD
Cinacalcet—Urticaria—Betamethasone—multiple sclerosis	0.000423	0.00162	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000422	0.00162	CcSEcCtD
Cinacalcet—Dizziness—Prednisolone—multiple sclerosis	0.000422	0.00162	CcSEcCtD
Cinacalcet—Asthenia—Triamcinolone—multiple sclerosis	0.000421	0.00161	CcSEcCtD
Cinacalcet—Abdominal pain—Betamethasone—multiple sclerosis	0.000421	0.00161	CcSEcCtD
Cinacalcet—Body temperature increased—Betamethasone—multiple sclerosis	0.000421	0.00161	CcSEcCtD
Cinacalcet—Abdominal pain—Dexamethasone—multiple sclerosis	0.000421	0.00161	CcSEcCtD
Cinacalcet—Body temperature increased—Dexamethasone—multiple sclerosis	0.000421	0.00161	CcSEcCtD
Cinacalcet—Asthenia—Methylprednisolone—multiple sclerosis	0.00042	0.00161	CcSEcCtD
Cinacalcet—Paraesthesia—Prednisone—multiple sclerosis	0.000416	0.00159	CcSEcCtD
Cinacalcet—Pruritus—Triamcinolone—multiple sclerosis	0.000415	0.00159	CcSEcCtD
Cinacalcet—Cough—Methotrexate—multiple sclerosis	0.000414	0.00159	CcSEcCtD
Cinacalcet—Pruritus—Methylprednisolone—multiple sclerosis	0.000414	0.00159	CcSEcCtD
Cinacalcet—Convulsion—Methotrexate—multiple sclerosis	0.000411	0.00157	CcSEcCtD
Cinacalcet—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000409	0.00415	CbGpPWpGaD
Cinacalcet—Dyspepsia—Prednisone—multiple sclerosis	0.000408	0.00156	CcSEcCtD
Cinacalcet—Arthralgia—Methotrexate—multiple sclerosis	0.000404	0.00155	CcSEcCtD
Cinacalcet—Chest pain—Methotrexate—multiple sclerosis	0.000404	0.00155	CcSEcCtD
Cinacalcet—Myalgia—Methotrexate—multiple sclerosis	0.000404	0.00155	CcSEcCtD
Cinacalcet—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000404	0.0041	CbGpPWpGaD
Cinacalcet—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000404	0.0041	CbGpPWpGaD
Cinacalcet—Decreased appetite—Prednisone—multiple sclerosis	0.000403	0.00154	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CXCL10—multiple sclerosis	0.000402	0.00408	CbGpPWpGaD
Cinacalcet—Rash—Prednisolone—multiple sclerosis	0.000402	0.00154	CcSEcCtD
Cinacalcet—Dermatitis—Prednisolone—multiple sclerosis	0.000402	0.00154	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000401	0.00154	CcSEcCtD
Cinacalcet—Diarrhoea—Methylprednisolone—multiple sclerosis	0.0004	0.00153	CcSEcCtD
Cinacalcet—Fatigue—Prednisone—multiple sclerosis	0.0004	0.00153	CcSEcCtD
Cinacalcet—Headache—Prednisolone—multiple sclerosis	0.0004	0.00153	CcSEcCtD
Cinacalcet—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000398	0.00404	CbGpPWpGaD
Cinacalcet—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000398	0.00404	CbGpPWpGaD
Cinacalcet—Constipation—Prednisone—multiple sclerosis	0.000396	0.00152	CcSEcCtD
Cinacalcet—Dizziness—Triamcinolone—multiple sclerosis	0.000388	0.00149	CcSEcCtD
Cinacalcet—Dizziness—Methylprednisolone—multiple sclerosis	0.000387	0.00148	CcSEcCtD
Cinacalcet—Infection—Methotrexate—multiple sclerosis	0.000385	0.00147	CcSEcCtD
Cinacalcet—Asthenia—Betamethasone—multiple sclerosis	0.000382	0.00146	CcSEcCtD
Cinacalcet—Asthenia—Dexamethasone—multiple sclerosis	0.000382	0.00146	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—CCL5—multiple sclerosis	0.000381	0.00387	CbGpPWpGaD
Cinacalcet—Nervous system disorder—Methotrexate—multiple sclerosis	0.00038	0.00145	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000379	0.00145	CcSEcCtD
Cinacalcet—Nausea—Prednisolone—multiple sclerosis	0.000379	0.00145	CcSEcCtD
Cinacalcet—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000378	0.00383	CbGpPWpGaD
Cinacalcet—Pruritus—Dexamethasone—multiple sclerosis	0.000377	0.00144	CcSEcCtD
Cinacalcet—Pruritus—Betamethasone—multiple sclerosis	0.000377	0.00144	CcSEcCtD
Cinacalcet—Skin disorder—Methotrexate—multiple sclerosis	0.000376	0.00144	CcSEcCtD
Cinacalcet—Vomiting—Triamcinolone—multiple sclerosis	0.000373	0.00143	CcSEcCtD
Cinacalcet—Vomiting—Methylprednisolone—multiple sclerosis	0.000372	0.00143	CcSEcCtD
Cinacalcet—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000372	0.00377	CbGpPWpGaD
Cinacalcet—Rash—Triamcinolone—multiple sclerosis	0.00037	0.00142	CcSEcCtD
Cinacalcet—Dermatitis—Triamcinolone—multiple sclerosis	0.00037	0.00142	CcSEcCtD
Cinacalcet—Anorexia—Methotrexate—multiple sclerosis	0.000369	0.00141	CcSEcCtD
Cinacalcet—Rash—Methylprednisolone—multiple sclerosis	0.000369	0.00141	CcSEcCtD
Cinacalcet—Dermatitis—Methylprednisolone—multiple sclerosis	0.000369	0.00141	CcSEcCtD
Cinacalcet—Urticaria—Prednisone—multiple sclerosis	0.000368	0.00141	CcSEcCtD
Cinacalcet—Headache—Triamcinolone—multiple sclerosis	0.000367	0.00141	CcSEcCtD
Cinacalcet—Headache—Methylprednisolone—multiple sclerosis	0.000367	0.0014	CcSEcCtD
Cinacalcet—Abdominal pain—Prednisone—multiple sclerosis	0.000366	0.0014	CcSEcCtD
Cinacalcet—Body temperature increased—Prednisone—multiple sclerosis	0.000366	0.0014	CcSEcCtD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000366	0.00372	CbGpPWpGaD
Cinacalcet—Diarrhoea—Dexamethasone—multiple sclerosis	0.000364	0.00139	CcSEcCtD
Cinacalcet—Diarrhoea—Betamethasone—multiple sclerosis	0.000364	0.00139	CcSEcCtD
Cinacalcet—Hypotension—Methotrexate—multiple sclerosis	0.000362	0.00139	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000353	0.00135	CcSEcCtD
Cinacalcet—Dizziness—Dexamethasone—multiple sclerosis	0.000352	0.00135	CcSEcCtD
Cinacalcet—Dizziness—Betamethasone—multiple sclerosis	0.000352	0.00135	CcSEcCtD
Cinacalcet—Nausea—Triamcinolone—multiple sclerosis	0.000348	0.00133	CcSEcCtD
Cinacalcet—Paraesthesia—Methotrexate—multiple sclerosis	0.000348	0.00133	CcSEcCtD
Cinacalcet—Nausea—Methylprednisolone—multiple sclerosis	0.000348	0.00133	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CCL5—multiple sclerosis	0.000346	0.00352	CbGpPWpGaD
Cinacalcet—Dyspnoea—Methotrexate—multiple sclerosis	0.000345	0.00132	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—CCR5—multiple sclerosis	0.000344	0.00349	CbGpPWpGaD
Cinacalcet—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000342	0.00347	CbGpPWpGaD
Cinacalcet—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000342	0.00347	CbGpPWpGaD
Cinacalcet—Hypersensitivity—Prednisone—multiple sclerosis	0.000342	0.00131	CcSEcCtD
Cinacalcet—Dyspepsia—Methotrexate—multiple sclerosis	0.000341	0.00131	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000339	0.00344	CbGpPWpGaD
Cinacalcet—Vomiting—Dexamethasone—multiple sclerosis	0.000338	0.0013	CcSEcCtD
Cinacalcet—Vomiting—Betamethasone—multiple sclerosis	0.000338	0.0013	CcSEcCtD
Cinacalcet—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000337	0.00342	CbGpPWpGaD
Cinacalcet—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000337	0.00342	CbGpPWpGaD
Cinacalcet—Decreased appetite—Methotrexate—multiple sclerosis	0.000337	0.00129	CcSEcCtD
Cinacalcet—Rash—Betamethasone—multiple sclerosis	0.000336	0.00129	CcSEcCtD
Cinacalcet—Rash—Dexamethasone—multiple sclerosis	0.000336	0.00129	CcSEcCtD
Cinacalcet—Dermatitis—Betamethasone—multiple sclerosis	0.000335	0.00128	CcSEcCtD
Cinacalcet—Dermatitis—Dexamethasone—multiple sclerosis	0.000335	0.00128	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000334	0.00128	CcSEcCtD
Cinacalcet—Fatigue—Methotrexate—multiple sclerosis	0.000334	0.00128	CcSEcCtD
Cinacalcet—Headache—Dexamethasone—multiple sclerosis	0.000333	0.00128	CcSEcCtD
Cinacalcet—Headache—Betamethasone—multiple sclerosis	0.000333	0.00128	CcSEcCtD
Cinacalcet—Asthenia—Prednisone—multiple sclerosis	0.000333	0.00127	CcSEcCtD
Cinacalcet—Pruritus—Prednisone—multiple sclerosis	0.000328	0.00126	CcSEcCtD
Cinacalcet—Diarrhoea—Prednisone—multiple sclerosis	0.000317	0.00121	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000317	0.00121	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—CCL3—multiple sclerosis	0.000316	0.00321	CbGpPWpGaD
Cinacalcet—Nausea—Betamethasone—multiple sclerosis	0.000316	0.00121	CcSEcCtD
Cinacalcet—Nausea—Dexamethasone—multiple sclerosis	0.000316	0.00121	CcSEcCtD
Cinacalcet—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000316	0.0032	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—CCR5—multiple sclerosis	0.000312	0.00317	CbGpPWpGaD
Cinacalcet—Urticaria—Methotrexate—multiple sclerosis	0.000308	0.00118	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—IL2RA—multiple sclerosis	0.000308	0.00312	CbGpPWpGaD
Cinacalcet—Dizziness—Prednisone—multiple sclerosis	0.000307	0.00117	CcSEcCtD
Cinacalcet—Abdominal pain—Methotrexate—multiple sclerosis	0.000306	0.00117	CcSEcCtD
Cinacalcet—Body temperature increased—Methotrexate—multiple sclerosis	0.000306	0.00117	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—PTGER4—multiple sclerosis	0.000304	0.00309	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PGR—multiple sclerosis	0.0003	0.00304	CbGpPWpGaD
Cinacalcet—Vomiting—Prednisone—multiple sclerosis	0.000295	0.00113	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—CXCR3—multiple sclerosis	0.000294	0.00298	CbGpPWpGaD
Cinacalcet—Rash—Prednisone—multiple sclerosis	0.000292	0.00112	CcSEcCtD
Cinacalcet—Dermatitis—Prednisone—multiple sclerosis	0.000292	0.00112	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—CD28—multiple sclerosis	0.000291	0.00296	CbGpPWpGaD
Cinacalcet—Headache—Prednisone—multiple sclerosis	0.00029	0.00111	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—CCR2—multiple sclerosis	0.000286	0.0029	CbGpPWpGaD
Cinacalcet—Hypersensitivity—Methotrexate—multiple sclerosis	0.000285	0.00109	CcSEcCtD
Cinacalcet—Asthenia—Methotrexate—multiple sclerosis	0.000278	0.00106	CcSEcCtD
Cinacalcet—Nausea—Prednisone—multiple sclerosis	0.000275	0.00105	CcSEcCtD
Cinacalcet—Pruritus—Methotrexate—multiple sclerosis	0.000274	0.00105	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—POMC—multiple sclerosis	0.000269	0.00273	CbGpPWpGaD
Cinacalcet—Diarrhoea—Methotrexate—multiple sclerosis	0.000265	0.00102	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—CNR1—multiple sclerosis	0.000264	0.00268	CbGpPWpGaD
Cinacalcet—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000264	0.00268	CbGpPWpGaD
Cinacalcet—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000264	0.00268	CbGpPWpGaD
Cinacalcet—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00026	0.00264	CbGpPWpGaD
Cinacalcet—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00026	0.00264	CbGpPWpGaD
Cinacalcet—Dizziness—Methotrexate—multiple sclerosis	0.000256	0.000981	CcSEcCtD
Cinacalcet—Vomiting—Methotrexate—multiple sclerosis	0.000246	0.000943	CcSEcCtD
Cinacalcet—Rash—Methotrexate—multiple sclerosis	0.000244	0.000935	CcSEcCtD
Cinacalcet—Dermatitis—Methotrexate—multiple sclerosis	0.000244	0.000935	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—POMC—multiple sclerosis	0.000244	0.00248	CbGpPWpGaD
Cinacalcet—Headache—Methotrexate—multiple sclerosis	0.000243	0.000929	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—CCL2—multiple sclerosis	0.000239	0.00242	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CXCL10—multiple sclerosis	0.000238	0.00241	CbGpPWpGaD
Cinacalcet—Nausea—Methotrexate—multiple sclerosis	0.00023	0.000881	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—TYK2—multiple sclerosis	0.000217	0.0022	CbGpPWpGaD
Cinacalcet—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000211	0.00214	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CD86—multiple sclerosis	0.000208	0.00211	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CCL5—multiple sclerosis	0.000205	0.00208	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—IL2—multiple sclerosis	0.000199	0.00201	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—SPP1—multiple sclerosis	0.000189	0.00192	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CCR5—multiple sclerosis	0.000184	0.00187	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000184	0.00187	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—IL2RA—multiple sclerosis	0.000182	0.00184	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—IL2—multiple sclerosis	0.00018	0.00183	CbGpPWpGaD
Cinacalcet—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000179	0.00181	CbGpPWpGaD
Cinacalcet—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000171	0.00173	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—APOE—multiple sclerosis	0.000168	0.0017	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000164	0.00166	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000163	0.00166	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CD80—multiple sclerosis	0.000152	0.00154	CbGpPWpGaD
Cinacalcet—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000145	0.00147	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—POMC—multiple sclerosis	0.000144	0.00146	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CCL2—multiple sclerosis	0.000141	0.00143	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—MAPK1—multiple sclerosis	0.000138	0.0014	CbGpPWpGaD
Cinacalcet—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000138	0.0014	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000131	0.00133	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000131	0.00133	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—TYK2—multiple sclerosis	0.000128	0.0013	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000128	0.0013	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000127	0.00129	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000125	0.00127	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000119	0.00121	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000119	0.00121	CbGpPWpGaD
Cinacalcet—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000112	0.00113	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—IL2—multiple sclerosis	0.000106	0.00108	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—IL6—multiple sclerosis	0.000106	0.00108	CbGpPWpGaD
Cinacalcet—Triflupromazine—BCHE—multiple sclerosis	0.000103	0.665	CrCbGaD
Cinacalcet—CASR—Signaling Pathways—MMP9—multiple sclerosis	0.000101	0.00102	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—SRM—multiple sclerosis	9.8e-05	0.000994	CbGpPWpGaD
Cinacalcet—CYP2D6—Biological oxidations—POMC—multiple sclerosis	9.08e-05	0.000921	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—STAT3—multiple sclerosis	8.96e-05	0.00091	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MYC—multiple sclerosis	8.33e-05	0.000845	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—TGFB1—multiple sclerosis	8.31e-05	0.000843	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—SRM—multiple sclerosis	8.3e-05	0.000842	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MAPK1—multiple sclerosis	8.15e-05	0.000827	CbGpPWpGaD
Cinacalcet—CYP1A2—Biological oxidations—POMC—multiple sclerosis	7.69e-05	0.000781	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	6.9e-05	0.0007	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	6.9e-05	0.0007	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—SRM—multiple sclerosis	6.4e-05	0.00065	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—GPC5—multiple sclerosis	6.31e-05	0.000641	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—IL6—multiple sclerosis	6.26e-05	0.000635	CbGpPWpGaD
Cinacalcet—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.94e-05	0.000602	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	5.85e-05	0.000593	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	5.85e-05	0.000593	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.71e-05	0.00058	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—GPC5—multiple sclerosis	5.35e-05	0.000543	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—RRM1—multiple sclerosis	5.23e-05	0.000531	CbGpPWpGaD
Cinacalcet—Fluoxetine—ALB—multiple sclerosis	5.15e-05	0.335	CrCbGaD
Cinacalcet—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	4.51e-05	0.000458	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	4.51e-05	0.000458	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—RRM1—multiple sclerosis	4.43e-05	0.00045	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—GPC5—multiple sclerosis	4.13e-05	0.000419	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.44e-05	0.000349	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.42e-05	0.000347	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—BCHE—multiple sclerosis	3e-05	0.000305	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.95e-05	0.0003	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.69e-05	0.000273	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—BCHE—multiple sclerosis	2.54e-05	0.000258	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.96e-05	0.000199	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—APOE—multiple sclerosis	1.81e-05	0.000183	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—POMC—multiple sclerosis	1.55e-05	0.000158	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—APOE—multiple sclerosis	1.53e-05	0.000155	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—ALB—multiple sclerosis	1.42e-05	0.000144	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—POMC—multiple sclerosis	1.32e-05	0.000133	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—ALB—multiple sclerosis	1.2e-05	0.000122	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—APOE—multiple sclerosis	1.18e-05	0.00012	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—POMC—multiple sclerosis	1.02e-05	0.000103	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—ALB—multiple sclerosis	9.25e-06	9.39e-05	CbGpPWpGaD
